Home
  >  
Section 61
  >  
Chapter 60,208

Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDfK

North, A.J.; Karas, J.A.; Ma, M.T.; Blower, P.J.; Ackermann, U.; White, J.M.; Donnelly, P.S.

Inorganic Chemistry 56(16): 9725-9741

2017


ISSN/ISBN: 1520-510X
PMID: 28766938
DOI: 10.1021/acs.inorgchem.7b01247
Accession: 060207693

Download citation:  
Text
  |  
BibTeX
  |  
RIS

This research aimed to develop new tumor targeted theranostic agents taking advantage of the similarities in coordination chemistry between technetium and rhenium. A γ-emitting radioactive isotope of technetium is commonly used in diagnostic imaging, and there are two β- emitting radioactive isotopes of rhenium that have the potential to be of use in radiotherapy. Variants of the 6-hydrazinonicotinamide (HYNIC) bifunctional ligands have been prepared by appending thioamide functional groups to 6-hydrazinonicotinamide to form pyridylthiosemicarbazide ligands (SHYNIC). The new bidentate ligands were conjugated to the tumor targeting peptides Tyr3-octreotate and cyclic-RGD. The new ligands and conjugates were used to prepare well-defined {M═O}3+ complexes (where M = 99mTc or natRe or 188Re) that feature two targeting peptides attached to the single metal ion. These new SHYNIC ligands are capable of forming well-defined rhenium and technetium complexes and offer the possibility of using the 99mTc imaging and 188/186Re therapeutic matched pairs.

PDF emailed within 0-6 h: $19.90